(AVCT.L) Avacta Group PLC Buy/Sell

Avacta Group plc

Notification of Results

Avacta Group plc, the company providing innovative, high value technologies and services to the pharmaceutical and diagnostics markets, will announce its results for the year ended 31 July 2009, on Thursday 26 November.

An analyst presentation will take place at the offices of Daniel Stewart & Company Plc, Becket House, 36 Old Jewry, London EC2R 8DD, on the day and those wishing to attend should contact Kathy Boate at the details below.

4 November 2009

Enquiries:

Avacta Group plc Tel: 0870 835 4367

Alastair Smith, Chief Executive Officer www.avacta.com
Haggie Financial LLP Tel: 020 7417 8989

Kathy Boate/Nicholas Nelson Kathy.boate@haggie.co.uk

Nominated Adviser: Tel: 020 7776 6550

Daniel Stewart & Company Plc Simon Leathers
Novum Securities Limited Tel: 020 7399 9400

Henry Turcan

Notes to Editors:

About Avacta

Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address unmet needs in the biopharmaceutical and healthcare sectors. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High end analytical instruments and leading edge contract research services are being provided to the biopharmaceutical and healthcare/personal-care materials sectors through the Group's biotech support division, Avacta Analytical. High value solutions for rapid, point of care diagnostics based on these core bio-analytical technologies, with a near term focus on veterinary diagnostics, are being delivered through Avacta Animal Health. Longer term these technologies will be transferred into the human clinical diagnostics market. Avacta listed on AIM in August 2006.

END